Edition:
United States

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

2.29USD
15 Nov 2018
Change (% chg)

-- (--)
Prev Close
$2.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,291
52-wk High
$4.08
52-wk Low
$2.11

Summary

Name Age Since Current Position

Edward Borkowski

58 2015 Independent Chairman of the Board

Johan Spoor

45 2016 President, Chief Executive Officer, Director

Maged Shenouda

53 2017 Chief Financial Officer, Executive Vice President - Corporate Development & Independent Director

Daniel Dupret

60 Chief Scientific Officer

James Pennington

75 2018 Chief Medical Officer

Charles Casamento

71 2017 Independent Director

Alastair Riddell

68 2015 Independent Director

Vern Schramm

76 2017 Independent Director

Biographies

Name Description

Edward Borkowski

Mr. Edward J. Borkowski, CPA, serves as Independent Chairman of the Board of the Company. He joined our Board of Directors in May 2015, and is currently the Chairman of the Board. Mr. Borkowski is a healthcare executive who previously served as the Chief Financial Officer of Concordia International, an international specialty pharmaceutical company. Prior to that, he was the Chief Financial Officer of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral controlled release products. Before working with Amerigen, he was the Chief Financial Officer and Executive Vice President of Mylan N.V. In addition, Mr. Borkowski previously held the position of Chief Financial Officer with Convatec, a global medical device company focused on wound care and ostomy, and Carefusion, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski also held senior financial positions at Pharmacia and American Home Products (Wyeth). He started his career with Arthur Andersen & Co. after graduating from Rutgers University with an MBA in accounting. Mr. Borkowski also graduated from Allegheny College with a degree in Economics and Political Science. He is currently a Trustee and an executive committee member of Allegheny College, and serves on the board of directors of Co-Diagnostics, Inc.

Johan Spoor

Mr. Johan M. (Thijs) Spoor is a President, Chief Executive Officer, Director of the Company. He has been our Chief Executive Officer since January 2016, President since April 2015, and Chairman from June 2014 to September 2015. From September 2010 until December 2015, he was the Chief Executive Officer of FluoroPharma Medical, Inc. (OTCQB: FPMI), where he served as Chairman of the Board from June 2012 until December 2015. From December 2008 until February 2010, he worked at Oliver Wyman as a consultant to pharmaceutical and medical device companies. Mr. Spoor was an equity research analyst at J.P. Morgan from July 2007 through October 2008 and at Credit Suisse from November 2005 through July 2007, covering the biotechnology and medical device industries. He holds a Pharmacy degree from the University of Toronto as well as an MBA from Columbia University.

Maged Shenouda

Mr. Maged S. Shenouda is Chief Financial Officer and Director of the Company. He joined our Board of Directors in October 2015 and was appointed to serve as the Company’s Chief Financial Officer in September 2017. Mr. Shenouda, a financial professional in the biotechnology industry, was the head of business development at Retrophin, Inc. from January 2014 until November 2014. From January 2012 until September 2013, he served as head of East coast operations for the Blueprint Life Science Group. Prior thereto, Mr. Shenouda was a financial analyst, first at UBS from January 2004 until March 2010 and later at Stifel Nicolaus from June 2010 until November 2011. He currently serves on the board of directors of Relmada Therapeutics, Inc. (OTCQB: RLMD). Mr. Shenouda received an MBA from Rutgers Graduate School of Management and BS in Pharmacy from St. John's College of Pharmacy. He is a Registered Pharmacist in New Jersey and California.

Daniel Dupret

Mr. Daniel Dupret serves as Chief Scientific Officer of the Company. He has served as President of AzurRx SAS since its formation in 2007, and as our Chief Scientific Officer since the acquisition of AzurRx SAS in June 2014. Previously, Dr. Dupret founded Proteus SA in 1998 and served as its President and Chief Executive Officer from 1998 to 2007. He founded Appligene SA in 1985 and served as its Chief Scientific Officer, then President and Chief Executive Officer until 1998. From 1982 to 1985, he served as project leader at Transgene SA. In parallel to his biotechnology career, Daniel Dupret served as an advisor for the French government and the European commission in connection with grant commission and funding of early-stage biotechnology companies. From 2003 to 2007, he served as President of the Board of the University of Nîmes.

James Pennington

Dr. James E. (Jim) Pennington is Chief Medical Officer of the company. He has over 30 years of experience in the pharmaceutical industry. Prior to joining the Company, Dr. Pennington served as Senior Clinical Fellow from 2010 to 2018 and Executive Vice President and Chief Medical Officer from 2007 to 2010 at Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH). From 2004 to 2007, Dr. Pennington served as Executive Vice President and Chief Medical Officer at CoTherix, Inc., and has served in various executive positions at a number of other pharmaceutical companies, including InterMune Inc., Shaman Pharmaceuticals and Bayer Corporation. In addition, Dr. Pennington has sat on several editorial boards, and has authored numerous original research publications and reviews. Dr. Pennington is currently a Clinical Professor of Medicine with the University of California San Francisco, where he has taught since 1986. Prior to that, he was a professor at Harvard Medical School. Dr. Pennington received a Bachelor of Arts from the University of Oregon and a Doctor of Medicine from the University of Oregon School of Medicine, and is Board Certified in internal medicine and infectious diseases.

Charles Casamento

Mr. Charles J. Casamento is an Independent Director of the company. He joined our Board of Directors in March 2017. Since 2007, he has been an executive director and principal of The Sage Group, a health care advisory group. In addition, Mr. Casamento is currently a member of the Fordham University Science Council. He was President and Chief Executive Officer of Osteologix from October 2004 until April 2007. He was the founder of Questcor Pharmaceuticals, where he was President, Chief Executive Officer and Chairman. At Questcor, he acquired Acthar, a product whose sales eventually exceeded $1.0 billion. At RiboGene, Inc. he was President, Chief Executive Officer and Chairman, and he was also co-founder, President and Chief Executive Officer of Indevus (formerly Interneuron Pharmaceuticals). He has held senior management positions at Genzyme Corporation, where he was Senior Vice President, American Hospital Supply, where he was Vice President of Business Development for the Critical Care Division, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. Mr. Casamento currently sits on the board of directors of International Stem Cell Corporation, Relmada Therapeutics Inc., and Eton Pharmaceuticals, Inc. He holds a Bachelor's Degree in Pharmacy from Fordham University in New York City and an MBA from Iona College in New Rochelle, New York.

Alastair Riddell

Dr. Alastair Riddell M.D. Ph.D. serves as Independent Director of the Company. He joined our Board of Directors in September 2015. He is also currently Chairman of a private UK biotech company, Nemesis Biosciences Ltd, Chairman of a UK AIM listed medical imaging company, Feedback plc, and Chairman of the South West Academic Health Science Network, which fosters links between the NHS, industry and universities. Dr. Riddell has over 30 years’ experience in the pharmaceutical, life science and biotech industries. After ten years directing phases 1-4 clinical trials of antibiotics, oncology and intensive care products for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as Chief Executive Officer for three UK biotech companies, Pharmagene Laboratories, Ltd. (“Pharmagene”), Paradigm Therapeutics, Ltd. (“Paradigm”), and Stem Cell Sciences, Inc. (“Stem Cell Sciences”). In these roles, he was the principal involved in the initial public offering of Pharmagene on the London Stock Exchange, and the sale of Paradigm and Stem Cell Sciences to Takeda in Japan and Stem Cells, Inc. in the U.S., respectively. Dr. Riddell has since had several roles in UK government initiatives related to promoting cooperation between pharmaceutical companies and the NHS and assessing projects for funding with Innovate UK. He began his career as a doctor in a variety of hospital specialties and in general practice. Dr. Riddell holds both Bachelor of Science and a Bachelor of Medical Sciences degrees, and was recently awarded a Doctorate of Science, Honoris Causa by Aston University.

Vern Schramm

Dr. Vern Schramm is an Independent Director of the company. He joined our Board of Directors in October 2017, and has served as a University Professor of the Albert Einstein College of Medicine since July 1999. Dr. Schramm served as the Chairman of the Department of Chemistry at the Albert Einstein College of Medicine until 2015. His fields of interest include enzymatic transition state analysis, transition state inhibitor design, biological targets for inhibitor design, and mechanisms of N-ribosyltransferases. Dr. Schramm was elected to the National Academy of Sciences in 2007, has been awarded the Ruth Merns Endowed Chair of Biochemistry, and served as the associate editor for the Journal of the American Chemical Society from 2003 to 2012. A frequent lecturer and presenter in topics related to chemical biology, Dr. Schramm has been a consultant and advisor to Pico Pharmaceuticals, Metabalon Biochemistry, Sirtris Scientific, and BioCryst Pharmaceuticals. Dr. Schramm obtained his BS in Bacteriology with an emphasis in chemistry from South Dakota State College, a Master’s Degree in Nutrition with an emphasis in biochemistry from Harvard University, and a Ph.D. in Mechanism of Enzyme Action, Department of Biochemistry, from Australian National University.

Basic Compensation

Name Fiscal Year Total

Edward Borkowski

205,000

Johan Spoor

546,458

Maged Shenouda

218,750

Daniel Dupret

204,215

James Pennington

--

Charles Casamento

--

Alastair Riddell

148,750

Vern Schramm

--
As Of  30 Dec 2016